Measurement of glucose-6-phosphate dehydrogenase and glutathione reductase activity in patients with paracoccidioidomycosis treated with ketoconazole.
Hemoglobin rates, hematocrit and glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase activities were measured in 38 patients with paracoccidioidomycosis treated with ketoconazole or sulfadoxin, and in 13 normal individuals. Ketoconazole-treated patients showed reduced G6PD and glutathione reductase activities. One of these patients was found to be G6PD-deficient and suffered a hemolytic episode during treatment, which, however, did not require interruption of therapy. The authors suggest that patients showing an erythrocyte enzyme defect should be monitored hematologically during treatment with ketoconazole. They also suggest that ketoconazole is an oxidant drug in addition to being a possible inhibitor of antioxidant erythrocyte enzymes.
Barraviera
B
B
Department of Infectious and Parasitologic Diseases, São Paulo, Brazil.
Mendes
R P
RP
Pereira
P C
PC
Machado
J M
JM
Curi
P R
PR
Meira
D A
DA
D000293:Adolescent; D000328:Adult; D000368:Aged; D004912:Erythrocytes / Q000201:enzymology*; D005954:Glucosephosphate Dehydrogenase / Q000097:blood*; D005980:Glutathione Reductase / Q000097:blood*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010229:Paracoccidioidomycosis / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D013413:Sulfadoxine / Q000627:therapeutic use
D006454:Hemoglobins; D013413:Sulfadoxine; D005954:Glucosephosphate Dehydrogenase; D005980:Glutathione Reductase; D007654:Ketoconazole